These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12759200)

  • 1. Postmarketing surveillance for drug abuse.
    Arfken CL; Cicero TJ
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S97-105. PubMed ID: 12759200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing surveillance of abuse liability of sibutramine.
    Arfken CL; Schuster CR; Johanson CE
    Drug Alcohol Depend; 2003 Mar; 69(2):169-73. PubMed ID: 12609697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
    French JA
    Epilepsia; 2002 Sep; 43(9):951-5. PubMed ID: 12199719
    [No Abstract]   [Full Text] [Related]  

  • 4. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States.
    Cicero TJ; Adams EH; Geller A; Inciardi JA; Muñoz A; Schnoll SH; Senay EC; Woody GE
    Drug Alcohol Depend; 1999 Nov; 57(1):7-22. PubMed ID: 10617309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
    BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
    [No Abstract]   [Full Text] [Related]  

  • 6. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance].
    Cossmann M; Kohnen C; Langford R; McCartney C
    Drugs; 1997; 53 Suppl 2():50-62. PubMed ID: 9190325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine: EMEA under industry's thumb.
    Prescrire Int; 2003 Jun; 12(65):102. PubMed ID: 12825579
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 16. The prescription drug user fee act: active postmarketing drug surveillance and safety.
    Lyles A
    Clin Ther; 2002 May; 24(5):800-2. PubMed ID: 12075947
    [No Abstract]   [Full Text] [Related]  

  • 17. European legislators tighten rules on drug safety.
    Watson R
    BMJ; 2012 Sep; 345():e6260. PubMed ID: 22991010
    [No Abstract]   [Full Text] [Related]  

  • 18. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 19. Compliance in European pharmacovigilance: a regulatory view.
    Arlett PR; Harrison P
    Pharmacoepidemiol Drug Saf; 2001; 10(4):301-2. PubMed ID: 11760490
    [No Abstract]   [Full Text] [Related]  

  • 20. Abuse, dependence, or withdrawal associated with tramadol.
    Brinker A; Bonnel RA; Beitz J
    Am J Psychiatry; 2002 May; 159(5):881; author reply 881-2. PubMed ID: 11986164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.